

ASX ANNOUNCEMENT

20 October 2020

Respiri Completes \$12.5 million Oversubscribed Share Placement

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce it has successfully completed an oversubscribed \$12.5 million share placement to institutional, professional and sophisticated Australian investors (Placement).

Mr Nicholas Smedley, Executive Chairman of Respiri said “On behalf of the Board of Directors of Respiri, I am delighted with the outcome of our oversubscribed capital raising, which has resulted in the Company raising \$12.5 million before costs of the offer and included a number of new institutional investors onto the share register with strong support from our existing investors. This additional funding provides Respiri with the financial flexibility to meet our stated corporate objectives, which in the near term supports the commercial launch of wheezo™ in Australia this quarter under our exclusive pharmacy partnership with Cipla and longer term supports commercial launches in key offshore markets including the US and Europe/UK. Moreover, the capital raised is expected to fully fund the Company to a sustainable cash flow breakeven position, which is forecast to occur in the second half of FY22.”

Placement

A total of 62.5 million new fully paid ordinary shares will be issued under the Placement at an issue price of \$0.20 per share, utilising the Company's available placement capacity pursuant to ASX Listing Rule 7.1 and 7.1A. The Placement price represents a 6.5% discount to the volume weighted average price (VWAP) of the Company's ordinary shares as traded on the ASX over the 30 days up to and including 13 October 2020.

The Company has released a prospectus to accompany the Placement, which was lodged this morning with the Australian Securities and Investment Commission (ASIC). The prospectus is being issued under section 708A(11) of the *Corporations Act 2001* (Cth) to remove any secondary trading restrictions on the on-sale of the Shares issued by the Company under the Placement and to the holder of the Placement shares.

Blue Ocean Equities acted as Lead Manager and Bookrunner for the Placement.

Use of Funds

Following the completion of the Placement, the Company will be in a strong financial position with approximately \$16.0 million in cash (excluding offer costs). Funds raised under the placement will be deployed in market development activities for the US and European market launches (\$1.6 million), sales and marketing initiatives (\$2.1 million), product development and research (\$1.5 million) and working capital, principally inventory build to meet expected demand for wheezo (\$6.5 million).

Timetable

The timetable for the Placement is highlighted in the table below. All dates are indicative and subject to change within the ASX Listing Rules and *Corporations Act 2001* (Cth).

Event	Date (2020)
ASX Announcements – Placement, Prospectus, Investor Presentation, Trading Halt Lifted	20 October
Settlement of Placement Shares	27 October
Allotment of Placement Shares on ASX	28 October

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respi Limited
 P: +61 408 462 873
 E: marjan@respi.co

Mr Nicholas Smedley
 Executive Chairman
 Respi Limited
 P: +61 447 074 160
 E: nicholas@respi.co

This ASX announcement dated 20 October 2020 has been authorised for release by the Board of Directors of Respi Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

™ wheezo is a trademark of Respi Limited